



ALOPECIA AREATA IN PERSONS OF COLOR: UNDERSTANDING UNMET PATIENT NEEDS AND TREATMENT STRATEGIES



References:

- Altunisik N, Ucuz I, Turkmen D. Psychiatric basics of alopecia areata in pediatric patients: evaluation of emotion dysregulation, somatization, depression, and anxiety levels. *J Cosmet Dermatol*. 2022;21(2):770-775. doi:10.1111/jocd.14122
- Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. *Nat Commun*. 2015;6:5966. doi:10.1038/ncomms6966
- Conic RZ, Miller R, Piliang M, Bergfeld W, Mesinkovska NA. Comorbidities in patients with alopecia areata. *J Am Acad Dermatol*. 2017;76(4):755-757. doi:10.1016/j.jaad.2016.12.007
- Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. *Australas J Dermatol*. 2019;60:163–170. doi:10.1111/ajd.12941
- Gip L, Lodin A, Molin L. Alopecia areata. A follow-up investigation of outpatient material. *Acta Derm Venereol*. 1969;49:180–188.
- King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med*. 2022;386(18):1687-1699. doi:10.1056/NEJMoa2110343
- King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the phase 3 randomized, controlled trial (THRIVE-AA1). *J Am Acad Dermatol*. 2024;91(5):880-888. doi:10.1016/j.jaad.2024.06.097
- King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. *Lancet*. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2
- King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. *J Am Acad Dermatol*. 2022;86(2):359-364. doi:10.1016/j.jaad.2021.08.043
- Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). *Am J Clin Dermatol*. 2023;24(3):443-451. doi:10.1007/s40257-023-00764-w
- Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2020;82(3):675-682. doi:10.1016/j.jaad.2019.08.032
- Leqselvi. Prescribing information. Sun Pharmaceutical Industries, Inc. Accessed March 4, 2025. https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2024/217900orig1s000correctedlbl.Pdf.
- Litfulo. Prescribing information. Pfizer Inc. Accessed March 4, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
- Ly S, Manjaly P, Kamal K, et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. *Am J Clin Dermatol*. 2023;24(6):875-893. doi:10.1007/s40257-023-00805-4
- Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol*. 2020;83(1):123-130. doi:10.1016/j.jaad.2020.03.004
- Okhovat J-P, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2023;88(5):1040-1050. doi:10.1016/j.jaad.2019.05.086
- Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines—part II. National Alopecia Areata Foundation. *J Am Acad Dermatol*. 2004;51:440–447. doi:10.1016/j.jaad.2003.09.032
- Olumiant. Prescribing information. Lilly USA LLC. Accessed March 4, 2025. https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2018/207924orig1s000lbl.Pdf.

ALOPECIA AREATA IN PERSONS OF COLOR: UNDERSTANDING UNMET PATIENT NEEDS AND TREATMENT STRATEGIES



- Patel HA, Revankar RR, Koblinski JE, et al. A clinician's guide to pediatric and adolescent alopecia areata treatments. *JAAD Reviews*. 2024;2:57-66. doi.org/10.1016/j.jdrv.2024.08.013
- Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. *Nat Rev Dis Primers*. 2017;3:17011. doi:10.1038/nrdp.2017.11
- Putterman E, Patel DP, Andrade G, et al. Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective, cross-sectional study. *J Am Acad Dermatol*. 2019;80(5):1389-1394. doi:10.1016/j.aad.2018.12.051
- Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. *J Eur Acad Dermatol Venereol*. 2024;38(4):687-694. doi:10.1111/jdv.19768
- Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: Clinical and laboratory monitoring. *Dermatol Ther (Heidelb)*. 2023;13(3):729-749. doi:10.1007/s13555-023-00892-5
- Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. *J Eur Acad Dermatol Venereol*. 2024;38(3):583-593. doi:10.1111/jdv.19665
- Sibbald C. Alopecia areata: an updated review for 2023. *J Cutan Med Surg*. 2023;27(3):241-259. doi:10.1177/12034754231168839
- Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol*. 2018;78(1):1-12. doi:10.1016/j.jaad.2017.04.1141
- Sy N, Mastacouris N, Strunk A, Garg A. Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis. *JAMA Dermatol*. 2023;159(4):419-423. doi:10.1001/jamadermatol.2023.0016
- Thompson AR, Tziotzios C, Nesnas J, Randall R, Czachorowski M, Messenger AG. Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study. *Br J Dermatol*. 2024;191(6):924-935. doi:10.1093/bjd/ljae307
- Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. *J Am Acad Dermatol*. 2006;55(3):438-441. doi:10.1016/j.jaad.2006.05.008
- Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. *J Eur Acad Dermatol Venereol*. Published online January 23, 2025. doi:10.1111/jdv.20526
- Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. *Front Immunol*. 2023;14:1152513. doi:10.3389/fimmu.2023.1152513
- Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. *J Eur Acad Dermatol Venereol*. 2001;15(2):137-139. doi:10.1046/j.1468-3083.2001.00229.x
- Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol*. 2020;183(4):702-709. doi:10.1111/bjd.18883
- Yi RC, Moran SK, Gantz HY, Strowd LC, Feldman SR. Biologics and small molecule targeted therapies for pediatric alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in the US: A narrative review. *Children (Basel)*. 2024;11(8):892. doi:10.3390/children11080892